[New Year's Message] Hanmi Pharm "Committed to R&D for Global Innovative Drug Development"

[Asia Economy Reporter Kim Daehyun] Hanmi Pharmaceutical has expressed its ambition to pour its capabilities into research and development (R&D) for the development of global innovative new drugs through solid growth.

On the 3rd, Hanmi Pharmaceutical CEOs Woo Jongsu and Kwon Sechang encouraged employees through a "New Year CEO Message," stating, "We will become a model in the industry through firm compliance and ethical management," and "Let us achieve 'sustainability' through substantial growth and complete 'innovative management.'"

On this day, Hanmi Pharmaceutical expressed gratitude to employees of group companies including Hanmi Science and Research Center, Paltan Industrial Complex, Pyeongtaek Bio Plant, Beijing Hanmi Pharmaceutical, Hanmi Fine Chemical, Online Pharm, Hanmi Healthcare, and JVM.

Last year, Hanmi Pharmaceutical achieved results such as ▲ licensing-out contract for FLT3 inhibitor (HM43239) ▲ FDA approval application for Poziotinib in the United States ▲ cumulative prescription sales of 1 trillion KRW for the Amozaratan family ▲ Rosuzet, the first single combination drug product to achieve prescription sales exceeding 100 billion KRW ▲ urology product group sales exceeding 100 billion KRW ▲ and achieving the No. 1 domestic outpatient prescription sales for four consecutive years.

CEOs Woo and Kwon emphasized, "In the deep tunnel of COVID-19, we may have to navigate another uncertain era where the future is unclear this year as well," adding, "Especially at times like this, we must take vigorous steps dreaming of the tiger’s leap forward."

They added, "Creativity and innovation do not exert their power in calm times," and "We must boldly pioneer new paths rather than walk the paths others have taken, and courageously advance the way we must go."

This content was produced with the assistance of AI translation services.